Lighting the Way to a Cure

  • Financials
  • Patient Library
  • Blog
  • Calendar
FSHD Header Logo
mobile-logo

  • Who We Are
        • About Us
          • History
          • Mission
          • Our Team
        • Our Impact
          • Therapeutic Accelerator
          • Education
          • Advocacy
          • Our Partners
        • Journey To A Cure
          • 2022 Donor Impact Report
  • Understanding FSHD
        • What is FSHD
          • Symptoms
          • Diagnosis
          • Early-onset FSHD
          • Genetic Testing
        • Living with FSHD
          • Newly Diagnosed?
          • Finding Care
          • Symptom Management
          • Patient Library
        • FSHD University
          • Physical Health
          • Wellness
          • Research
  • Get Involved
        • Support Us
          • Ways to Give
          • Become a Torchbearer
          • Raise Awareness
          • Volunteer
          • Fundraise
        • Advance Research
          • Patient Involvement
          • True Cost of FSHD Study
          • Clinical Trials
          • Donate tissue
        • Connect
          • Find Your Local Chapter
          • Join the Community
          • World FSHD Alliance
          • Online Communities
        • Events
          • Walk & Roll to Cure FSHD
          • Events Calendar
          • FSHD 360 Regional Conferences
          • FSHD Connect Conference
  • Research
        • For Patients & Families
          • Advance Research
          • True Cost of FSHD Study
          • TestFSHD genetic testing
          • Clinical Trials
        • For Researchers
          • Apply for a Grant
          • Research We Have Funded
          • Resources
          • Int’l Research Congress
        • For Clinicians
          • FSHD Masterclass
          • ICD-10
        • Global Collaboration
          • Therapeutic Accelerator
          • Clinical Trial Research Network
          • Drug Development Pipeline
          • Project Mercury
  • News
    • Media Library
    • Blog
      • Living with FSHD
        • Health and Medicine
        • PT and Exercise
        • Tips and Tricks
        • Mental Health
      • FSHD Society News
      • FSHD Research
      • Fundraising & Events
      • Media & PR
    • FSHD Society Radio
    • The FSHD Advocate
  • JOIN US
  • Donate
  • JOIN US
  • Donate

Losmapimod continues to show promise

Home / FSHD Research / Losmapimod continues to show promise

Posted on: Oct 31, 2022

Steady improvement seen in data from open-label extension study

Losmapimod, a drug that is currently in a Phase 3 clinical trial for FSH muscular dystrophy, continues to slow or stop the progression of disease in patients who have been taking the drug for up to 96 weeks, according to Fulcrum Therapeutics, the Cambridge, Massachusetts-based company that is developing the therapy. Jenny Shoskes, PharmD, from Fulcrum presented the data in early October at the World Muscle Society Congress in Halifax, Canada.

The data were collected from individuals who had participated in the Phase 2 study of the drug that was completed in 2021 and then opted to continue in an “open-label extension” (OLE) study in which all participants were offered losmapimod for an additional 48 weeks.

In the Phase 2 study, called ReDUX4, half of the participants were assigned at random to take 15 mg losmapimod twice daily and half received placebo. The trial was “double blind,” meaning that neither the participants nor researchers conducting the study knew who was receiving drug or placebo. At the end of the initial 48-week study period, all participants were offered the option to join the open-label extension, in which everyone who was on placebo was switched to losmapimod and all who started on losmapimod continued on losmapimod. Of the 77 participants who completed the initial 48-week study, 76 enrolled in the OLE. At week 96, 74 participants remained on treatment.

“Losmapimod can provide meaningful benefits”

In the ReDUX4 trial, individuals who had been on placebo experienced disease progression as shown by a decline in the range of motion of their arms (“reachable workspace” or RWS). From this placebo group, 36 individuals joined the open-label study and went on losmapimod for 48 weeks. This group, which had previously lost range of arm motion, demonstrated trends of slowing or stopping loss of muscle function, as measured by RWS. Participants who originally received losmapimod and remained on therapy (38 people), continued to show slowing or stopping of disease progression and demonstrated improvement in muscle function, as measured by RWS. (See graph below.)

Through the 96 weeks of the ReDUX4 and OLE study, losmapimod was generally safe and well tolerated by the participants. “No treatment-related serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) leading to study drug discontinuation were reported through 96 weeks of dosing,” Fulcrum noted.

“Every FSHD patient faces relentless and accumulating muscle and functional loss. These long-term data further demonstrate that losmapimod can provide meaningful benefits to patients living with this relentless, debilitating disease,” said Bryan Stuart, chief executive officer at Fulcrum. “The sustained ability to slow or halt the progression of FSHD over two years underscores the significance of our Phase 3 REACH trial and the potential of losmapimod to be the first approved treatment for FSHD.”

Fulcrum is currently investigating losmapimod in the ongoing Phase 3 REACH trial. For more information about the trial please visit https://clinicaltrials.gov/ct2/show/NCT05397470.

These two graphs show the percent of change from baseline in the range of arm motion (“reachable workspace” or RWS) in participants’ dominant arm (left graph) and non-dominant arm (right graph). In the study, participants held a weight (500 g) in each arm while performing the RWS task, which enhanced the sensitivity of the measurement. The participants who took losmapimod (solid orange line) showed no change in RWS, and even an improvement in the non-dominant arm through the duration of the ReDUX4 and open-label extension (OLE). In contrast, participants who were on placebo (blue dashed line) had a loss of RWS, as much a 10% by 48 weeks, but when they began taking losmapimod (dashed orange line), the loss of RWS stabilized and even improved, as seen by the upward slope of the line.
Share

Filed Under: FSHD Research

Comments

  1. Serhii_Sh says

    October 31, 2022 at 4:56 pm

    If a drug is approved for patients over 18, what will it mean for children?
    Will more years of testing be needed?

    Reply
    • Debbie says

      December 24, 2022 at 12:06 am

      This is my question as well. I have a 13 year old who will be approximately 15 when phase 3 ends. How old will FSHD patients have to be to receive the medication if it’s approved?

      Reply
  2. V says

    October 31, 2022 at 5:37 pm

    Ok so why not allow expanded access now for those most severely affected and do not qualify for the trial?

    Reply
    • T says

      December 2, 2022 at 12:17 am

      I agree with you wholeheartedly. I was told by my doctors at barnes jewish that the expanded access wasn’t yet ready because of “lack of resources” or “not enough of the drug” or whatever. If that’s the case why even have expanded access in the first place?????????

      Reply
  3. Good says

    November 4, 2022 at 9:10 am

    cool news

    Reply
  4. Robert says

    November 4, 2022 at 12:39 pm

    I am one the early participants on the initial trial and I feel that it the drug is at least slowing the progression. Time will tell as the participation increases in phase 3.

    Reply
  5. cool says

    November 6, 2022 at 12:10 am

    Good news

    Reply
  6. Cihan says

    November 6, 2022 at 9:33 am

    Ben FSH kas hastasıyım bu ilaç nezaman çıkacak

    Reply
  7. Richard Hobbs says

    December 20, 2022 at 1:15 pm

    Is this trial closed for new participants? I was recently diagnosed with FSHD.

    If not how do I find out about any new or upcoming trials?

    Thanks

    Reply
  8. Anonymous says

    December 24, 2022 at 12:08 am

    How old will patients need to be if the drug is approved?

    Reply
    • jkinoshita says

      January 4, 2023 at 1:49 pm

      If and when the drug is approved by the FDA, doctors will most likely be able to prescribe it to patients of any age. What is unknown is whether insurance companies will refuse to pay for treatment for certain individuals.

      Reply
  9. Jack Degan says

    February 1, 2023 at 6:21 pm

    Hello,
    Are these dates typically consistent? Conservative date? Realistic date? Padded date?:
    ClinicalTrials.Gov – (FSHD) (Reach)
    Actual Study Start Date: June 16, 2022
    Estimated Primary Completion Date: March 2024
    Estimated Study Completion Date: March 2024

    Reply
  10. Angelika Schnappauf says

    February 13, 2023 at 11:08 am

    Wo kann ich mich für die neue Losmapimod-Studie die demnächst in München starten soll bewerben?

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

SEARCH

Categories

  • FSHD Research
  • FSHD Society News
    • Extraordinary Measures
    • Journey to a Cure
  • Fundraising & Events
  • General
  • Living with FSHD
    • Health and Medicine
    • Mental Health
    • PT and Exercise
    • Tips and Tricks
  • Media & PR

Sign up for Email Alerts

Stay up to date with the latest FSHD news and updates from FSHD Society.

CONNECT WITH US

Proud Member World FSHD Alliance (1)
Footer-Logo-min

General Mailing Address:

75 North Main Street, Suite 1073
Randolph, MA 02368 U.S.A.

Mail Donations to:

Department 960
PO Box 4106
Woburn, MA 01888-4106

(781) 301-6060

  • DONATE
  • Donate
  • Join Us
  • Inclusivity & Equity
  • Privacy Policy
  • Contact Us
  • Glossary Of Scientific Terms
Digital Marketing by